Source link : https://www.newshealth.biz/health-news/fda-oks-esketamine-nasal-spray-monotherapy-for-depression/
The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in adults with major depressive disorder who have not responded adequately to at least two oral antidepressants. The FDA first approved esketamine nasal spray for treatment-resistant […]
Author : News Health
Publish date : 2025-01-24 17:22:43
Copyright for syndicated content belongs to the linked Source.